Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 ...

See, LLY stock warrants your attention. Why? Because it offers monopoly-like high margins at a discounted price.

Eli Lilly signed an agreement with Cipla, allowing the Indian drugmaker to sell its blockbuster weight-loss drug under a ...

Eli Lilly was looking for infrastructure and an uncomplicated permit process for its $6.5M pharmaceutical manufacturing ...

Eli Lilly and Company is a Strong Buy due to strong growth in obesity and diabetes drugs and pipeline innovation. Learn more ...

Eli Lilly said Friday it is set to acquire clinical-stage company Adverum Biotechnologies for up to $12.47 a share, including milestone payments.

India’s CDSCO has withdrawn Baricitinib’s COVID-19 use after Eli Lilly’s request, citing reduced need for emergency drugs.

Analysts say that while the deal is a positive for the stock, it has already been priced in and investors are now resorting ...

Eli Lilly (NYSE: LLY) has been one of the best-performing healthcare giants over the past decade. It now stands as the ...

Florida-based wealth advisory J. L. Bainbridge disclosed a purchase of Eli Lilly and Company valued at approximately $45.6 ...

Shares of Cipla fell more than 3 per cent on Friday after the drugmaker announced a partnership with US pharmaceutical major ...

Eli Lilly has teamed up with Cipla to market its popular weight-loss drug Mounjaro in India. The medication, which is used ...